ESG421

ESG421 is an investigational antibody-drug conjugate (ADC) being developed by Shanghai Escugen Biotechnology for the treatment of solid tumors. The drug consists of a monoclonal antibody targeting an undisclosed cell-surface antigen, conjugated to a cytotoxic payload via a linker. As of early 2024, the specific molecular target and the nature of the payload remain confidential. ESG421 is part of Escugen's extensive ADC pipeline, which focuses on utilizing proprietary conjugation technologies to improve the therapeutic index of cancer treatments. It is currently in the early stages of development for various solid tumor indications.